Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy
Pharma
Sarepta's Elevidys off to strong start despite label restriction
Even before a potential label expansion, the gene therapy has raked in around $69 million since its launch.
Zoey Becker
Nov 2, 2023 4:21pm
FDA signs off on Santhera's muscular dystrophy drug Agamree
Oct 27, 2023 8:23am
Sarepta pawns off PRV for $102M to unidentified buyer
Jul 6, 2023 8:10am
'The Top Line': Sarepta's DMD trial, Illumina's Grail quest
Sep 9, 2022 6:00am
Samsung Biologics, GSK, Fujifilm and more—Fierce Pharma Asia
Jan 28, 2022 10:15am
FDA waves through a 3rd Sarepta drug on dystrophin data
Feb 26, 2021 10:56am